Overbrook Management Corp’s AstraZeneca AZN Stock Holding History

Overbrook Management Corp’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,032	Closed	-$204K	–	70
2026 Q1	$204K	Buy	+1,032	New	+$199K	0.04%	51

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Overbrook Management Corp's AZN Position: Q2 2026 in Review

Overbrook Management Corp sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 1,032 shares — an estimated $204K sold.

Overbrook Management Corp first reported a position in AZN in Q1 2026 and held it in 1 quarter. The position peaked at $204K in Q1 2026. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Overbrook Management Corp reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Overbrook Management Corp sold 1,032 AstraZeneca shares in Q2 2026, an estimated $204K.
Overbrook Management Corp first reported a position in AstraZeneca in Q1 2026 and held it in 1 quarter.
Overbrook Management Corp's AstraZeneca position peaked at $204K in Q1 2026.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Overbrook Management Corp's 13F filing for Q2 2026, filed 30 Jul 2026.